share_log

HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15

HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15

HC Wainwright & Co.維持對Aurinia Pharmicals的買入,將目標股價提高至15美元
Benzinga ·  2023/08/07 12:02

HC Wainwright & Co. analyst Ed Arce maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $14 to $15.

HC Wainwright&Co.分析師埃德·阿爾斯維持金光製藥(納斯達克:AUPH)的買入,並將目標價從14美元上調至15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論